Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States.

ABSTRACT:

Background

Severe aplastic anemia (SAA) is a rare autoimmune condition resulting in low blood cell counts across lineages. Immunosuppressive therapy (IST) has demonstrated low response, toxicity, and risk of transformation. In a Phase I/II trial, the addition of eltrombopag to first-line IST increased response rates relative to an IST-only historical cohort.

Methods

A model was developed to estimate the budget impact of treating SAA with eltrombopag-based therapy from a US private healthcare system perspective. A simulated cohort of newly diagnosed SAA patients based on the total US population received 6 months of IST ± eltrombopag and were followed for 1 year, with mutually exclusive patient cohorts entering in years 1, 2, and 3. The model assessed the budget impact of firs

SUBMITTER: Tremblay G 

PROVIDER: S-EPMC6858800 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature